Work

Gankyrin‐Protein Interactions in GI Cancers: A Novel Target of New Therapeutics

Year: 2025

Type: article

Abstract: Gankyrin (PSMD10) is a 25 kDa oncogenic protein and regulatory subunit of the 26S proteasome, characterized by a sevenfold ankyrin repeat domain. Gankyrin is overexpressed in various malignancies, particularly gastrointestinal (GI) cancers. Gankyrin contributes to tumorigenesis by modulating key signaling pathways and engaging in oncogenic protein-protein interactions with tumor suppressors, including p53 and Rb, thereby promoting cell proliferation, metastasis, and resistance to treatment. Recent advances have shed light on the structural basis of gankyrin's molecular interactions, its potential as a diagnostic and prognostic biomarker, and emerging therapeutic strategies. Together, targeting gankyrin represents a promising strategy for precision oncology in GI cancers.

Source: Chronic Diseases and Translational Medicine

DOI: 10.1002/cdt3.70025

Authors: Shuang Li, Yuky Lam, Aaron Muth, Zhe‐Sheng Chen, Shanzhi Wang

Institutions: Columbia University Irving Medical Center, St. John's University

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: St. John's University